Nuwellis, Inc. (NUWE)
| Market Cap | 255.05K -95.4% |
| Revenue (ttm) | 8.77M -0.2% |
| Net Income | -19.04M |
| EPS | -563.49 |
| Shares Out | 146.58K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,870,546 |
| Open | 1.740 |
| Previous Close | 4.450 |
| Day's Range | 1.610 - 1.930 |
| 52-Week Range | 1.610 - 378.347 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Pra... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsNews
Nuwellis prices $3.4M at-the-market offering at $2.59 per share
Nuwellis (NUWE) announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common...
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warran...
Why Is Penny Stock Nuwellis (NUWE) Up Today?
Nuwellis stock was on the rise after the company announced a study that was published in a peer-reviewed journal.
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patients Peer-reviewed rese...
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its exp...
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuw...
Nuwellis awarded U.S. patent for Dual Lumen Catheter
Nuwellis (NUWE) announced that the U.S. Patent and Trademark Office , or USPTO, has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a peripheral dual-lumen catheter desi...
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalities Innovation enables customiz...
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its par...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the fiv...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Inc trading halted, news pending
19:50 EDT Nuwellis (NUWE) Inc trading halted, news pending
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations
MINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its exp...
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-...
Nuwellis highlights clinical utility of its Aquadex SmartFlow system
Nuwellis (NUWE) highlighted the clinical utility of its Aquadex SmartFlow system at the 4th annual Critical Care Cardiology Education Summit, hosted by the University of Minnesota. As part of the…
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit
MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the c...
Nuwellis CEO transition to transition out of role, Mike McCormick to succeed
Nuwellis (NUWE) announced the appointment of Mike McCormick as CEO, effective June 30. John Erb, who currently serves as president, CEO, and chairman of the board, will transition from his…
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of th...
Nuwellis expands collaboration with South Carolina healthcare system
Nuwellis (NUWE) announced an expanded collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow devices into the clinical care programs at one of its children’s hospit...
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology South Carolina healthcare provider also upgrades to latest Aquadex devic...
Nuwellis Announces Closing of $6.0 Million Registered Public Offering
MINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces ...
Nuwellis 20M share secondary priced at 30c
Nuwellis (NUWE) announces the pricing of a public offering of 20M shares of its common stock with accompanying warrants to purchase common stock for gross proceeds of approximately $6M. The…
Nuwellis Announces Pricing of $6 Million Public Offering
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces t...
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.